Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-α and IL-6 receptor targeted therapies in refractory Takayasu arteritis

Clinical and Experimental Rheumatology

Volumn 32, Issue SUPPL.82, 2014, Pages

  Youngstein, Taryn ^a   Peters, James E ^a   Hamdulay, Shahir S ^b   Mewar, Devesh ^c   Price Forbes, Alec ^d   Lloyd, Mark ^e   Jeffery, Rachel ^f   Kinderlerer, Anne R ^g   Mason, Justin C ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL COVENTRY   (United Kingdom)

^e FRIMLEY PARK HOSPITAL   (United Kingdom)

^f NORTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^g ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Anti TNF ; IL 6; Large vessel vasculitis; Stenosis; Takayasu arteritis

Indexed keywords

ADALIMUMAB; CYCLOPHOSPHAMIDE; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ANTAGONIST; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AORTA ARCH SYNDROME; ARTERY INJURY; ARTERY OCCLUSION; ARTICLE; COHORT ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; DISEASE RESISTANCE; DISEASE SEVERITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INDIAN TAKAYASU ARTERITIS ACTIVITY AND DAMAGE SCORE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PRESCRIPTION; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTERIAL OCCLUSIVE DISEASES; BIOLOGICAL THERAPY; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DRUG MONITORING; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; PREDNISONE; RECEPTORS, INTERLEUKIN-6; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TAKAYASU ARTERITIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901929046     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. PARK MC, LEE SW, PARK YB, LEE SK: Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford) 2006; 45: 545-8.
2. MASON JC: Takayasu arteritis--advances in diagnosis and management. Nat Rev Rheumatol 2010; 6: 406-15.
3. MUKHTYAR C, GUILLEVIN L, CID MC et al.: EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68: 318-23.
4. PIPITONE N, OLIVIERI I, SALVARANI C: Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agents. Clin Exp Rheumatol 2012; 30 (Suppl. 70): S139-61.
5. MAKSIMOWICZ-McKINNON K, CLARK TM, HOFFMAN GS: Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 2007; 56: 1000-9.
6. MOLLOY ES, LANGFORD CA, CLARK TM, GOTA CE, HOFFMAN GS: Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 2008; 67: 1567-9.
7. NISHIMOTO N, NAKAHARA H, YOSHIO-HOSHINO N, MIMA T: Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008; 58: 1197-200.
8. QUARTUCCIO L, SCHIAVON F, ZULIANI F et al.: Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. Clin Exp Rheumatol 2012; 30: 922-8.
9. BREDEMEIER M, ROCHA CM, BARBOSA MV, PITREZ EH: One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab. Clin Exp Rheumatol 2012; 30 (Suppl. 70): S98-100.
10. XENITIDIS T, HORGER M, ZEH G, KANZ L, HENES JC: Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis. Rheumatology (Oxford) 2013; 52: 1729-31.
11. AREND WP, MICHEL BA, BLOCH DA et al.: The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990; 33: 1129-34.
12. MISRA R, DANDA D, RAJAPPA SM et al.: Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford) 2013; 52: 1795-801.
13. SIVAKUMAR R: Outcome of Vascular Interventions in Takayasu Arteritis Using the Takayasu Arteritis Damage Score. Arthritis Rheum 2011; 63 (Suppl. 10): 1504.
14. TEAM RDC R: A language and environment for statistical computing. Vienna: R Foundation for statistical computing; 2011.
15. TAKEUCHI T, TANAKA Y, AMANO K et al.: Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study. Rheumatology (Oxford) 2011; 50: 1908-15.
16. KOTTER I, HENES JC, WAGNER AD, LOOCK J, GROSS WL: Does glucocorticosteroid- resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol 2012; 30 (Suppl. 70): S114-29.
17. TRIPATHY NK, GUPTA PC, NITYANAND S: High TNF-alpha and low IL-2 producing T cells characterize active disease in Takayasu's arteritis. Clin Immunol 2006; 118: 154-8.
18. COMARMOND C, PLAISIER E, DAHAN K et al.: Anti TNF-alpha in refractory Takayasu's arteritis: Cases series and review of the literature. Autoimmun Rev 2012; 11: 678-84.
19. SCHMIDT J, KERMANI TA, BACANI AK, CROWSON CS, MATTESON EL, WARRINGTON KJ: Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long-term followup. Arthritis Care Res 2012; 64: 1079-83.
20. MEKINIAN A, NEEL A, SIBILIA J et al.: Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford) 2012; 51: 882-6.
21. UNIZONY S, STONE JH, STONE JR: New treatment strategies in large-vessel vasculitis. Curr Opin Rheumatol 2013; 25: 3-9.
22. SALVARANI C, MAGNANI L, CATANOSO M et al.: Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012; 51: 151-6.
23. SEITZ M, REICHENBACH S, BONEL HM, ADLER S, WERMELINGER F, VILLIGER PM: Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011; 141: w13156.
24. UNIZONY S, ARIAS-URDANETA L, MILOSLAVSKY E et al.: Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res 2012; 64: 1720-9.
25. SALVARANI C, MAGNANI L, CATANOSO MG et al.: Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-alpha blockers. Clin Exp Rheumatol 2012; 30 (Suppl. 70): S90-3.
26. HERNANDEZ-RODRIGUEZ J, SEGARRA M, VILARDELL C et al.: Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003; 107: 2428-34.